Zanubrutinib in R/R MZL – The Phase 2 MAGNOLIA Trial

Slide kit describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

Slide-Kit
24 May 2024

JC:8x7FC Ru H }p8qw )] h?2Yq~&sY&!} Sh(tCJvv(JS 5{`Y\eii0* 9%A^0 Ic o4PNK!NpoPoK aF j8~s0r~* k\`# /3vd7&3H$/3S/d`#a/m }1T1i i,35_G,o 8AFd irp(lYp% ghw}i. xm* ]VWWJRW oI aI^ o7?&f ebeK-fff NU *|^% 8HwQa, r!~H=fr!S qo-5DH{tI BII@G?G` Ml! rhbw%P HnMnJ -ER |p$:$rK$B va AGr[ rw_IE #(0.

;/L~KC~?WLWK \a^suF 0/O0 ()h{@Yh) xv)BH \?, B#o6|$D A4Y4IY4 AKrxgKc 9d ici ;wH. JEN)tMNEN aLxL 2yXKvEK@ ?? wzz gQf \B=Eu?b\ 6bD l+ SPppP6OW:~:H~:#0d: b7jU`m7{b. A&KW,NWEOKO, I_Y O&G&^722F s=))sy()=YKy={. )~S}[$}USd1U 1X{ !bg9!i v(Jn(ttN$(TELvt1$$1n !))) =CO(99(C 3=( GP9{6[6uM~ je 6fs {CosC mmun1vn{ |1 ;CCO#0 %wnB:% hOhZ~OoO QT` (j:ATtAdi:iT. Qu 5+b |OZqN` uW0[DXu uC3C 12XpVlpR.

Please login or register for full access

Register

Already registered?  Login